GlassScriptPhysician profile
Karla Ostaszewski
NPI 1972162337
$5,515.73
in general payments reported to CMS, 2019-2025
20 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,212 · 2023: $1,340 · 2024: $1,152 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,143 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,143.25 |
| Education | $160.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,471.75 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,071.88 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $744.38 | 2022-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $622.69 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $361.99 | 2022-2025 | Hyqvia, Cuvitru, Takhzyro |
| Amgen INC. | $219.97 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $174.34 | 2022-2025 | |
| Csl Behring | $133.24 | 2022-2025 | Hizentra |
| Kaleo, INC. | $131.57 | 2022-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.82 | 2022-2023 | Spiriva Respimat |
| Genentech USA, INC. | $103.60 | 2023-2025 | Xolair |
| Alk-Abello, INC | $88.82 | 2022-2025 | Odactra, Ragwitek, Grastek |
| Ars Pharmaceuticals Operations, INC. | $70.74 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $67.99 | 2024 | |
| Aimmune Therapeutics, INC. | $47.82 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $23.61 | 2023 | Opzelura |
| Seqirus USA INC | $20.07 | 2024 | Flucelvax, Fluad |
| Covis Pharma Gmbh | $19.65 | 2022 | |
| Phadia US INC. | $17.98 | 2022 | |
| Leo Pharma INC. | $17.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Ostaszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.